Study S001108

An Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of Multiple Weekly Doses of NNC0165-1562 and Semaglutide in Subjects With Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03574584
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 37
Start: 2018-06-18
Primary completion: 2019-07-27
Lead sponsor: Novo Nordisk A/S
Conditions: Metabolism and Nutrition Disorders; Overweight or Obesity
Interventions: DRUG:NNC0165-1562; DRUG:Semaglutide; DRUG:Placebo (NNC0165-1562)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1191-5147

Registered primary outcomes

Number of treatment emergent adverse events (TEAEs) [Week 0-25]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.